Crude extracts from Andrographis paniculata

Abstract

This invention relates to a method of inhibiting TNFα or IL-1β expression with an extract of Andrographis paniculata. The extract contains andrographolide, 14-deoxy-andrographolide, 14-deoxy-11,12-dehydrogen-andrographolide, and neoandrographolide.

1. A method of treating an inflammatory bowel disease in a subject in need thereof, comprising administering to the subject an effective amount of an extract of Andrographis-paniculata, wherein the extract contains 2-20% by weight andrographolide, 1-6% by weight 14-deoxy-andrographolide, 1-12% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide. 
     
     
       2. The method of  claim 1 , wherein the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. 
     
     
       3. The method of  claim 2 , wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrograpliolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide. 
     
     
       4. The method of  claim 1 , wherein the inflammatory bowel disease is Crohn's disease. 
     
     
       5. The method of  claim 1 , wherein the inflammatory bowel disease is ulcerative colitis. 
     
     
       6. The method of  claim 5 , wherein the extract contains 3-8% by weight andrographolide, 3-5% by weight 14-deoxy-andrographolide, 7-9% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. 
     
     
       7. The method of  claim 6 , wherein the extract contains 4.2% by weight andrographolide, 4.4% by weight 14-deoxy-andrographolide, 8% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2.1% by weight neoandrographolide. 
     
     
       8. An extract of Andrographis paniculata for treating effectively an inflammatory bowel disease in a subject in recognized need thereof, comprising: 2-20% by weight andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and further comprising in said extract for treating effectively an inflammatory bowel disease, 1-5% by weight neoandrographolide. 
     
     
       9. The extract of claim 8, wherein said extract comprises 3-8% by weight andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. 
     
     
       10. An extract of Andrographis paniculata, for treating effectively an inflammatory bowel disease in a subject in recognized need thereof, comprising: 2-20% by weight andrographolide, 14-deoxy-andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and further comprising in said extract for treating effectively an inflammatory bowel disease, 1-5% by weight neoandrographolide. 
     
     
       11. The extract of claim 10, wherein said extract comprises 3-8% by weight andrographolide, 14-deoxy-andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 2-4% by weight neoandrographolide. 
     
     
       12. A pharmaceutical composition for treating effectively an inflammatory bowel disease in a subject in recognized need thereof, comprising an extract of Andrographis paniculata, comprising: 2-20% by weight andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide and further comprising a pharmaceutical composition for treating effectively an inflammatory bowel disease in a subject in recognized need thereof, a pharmaceutically acceptable carrier. 
     
     
       13. A pharmaceutical composition for treating effectively an inflammatory bowel disease in a subject in recognized need thereof, comprising an extract of Andrographis paniculata, comprising: 2-20% by weight andrographolide, 14-deoxy-andrographolide, 1.0-7% by weight 14-deoxy-11,12-dehydrogen-andrographolide, and 1-5% by weight neoandrographolide and further comprising a pharmaceutical composition for treating effectively an inflammatory bowel disease in a subject in recognized need thereof, a pharmaceutically acceptable carrier.